Excellent quality and fast dispatch
Products arrived well-packaged with COA documentation included. Really appreciate the clear research-only labelling — exactly what I needed for my lab work.
James R.
Sydney, AU
GH axis & performance research
CJC-1295 No DAC Australia
Everything researchers need to know about CJC-1295 No DAC — mechanism, published dosing protocols, side effect profiles, reconstitution, and how to source third-party tested CJC-1295 No DAC in Australia.
Quick facts
- Also known as: Modified GRF 1-29
- Form: Lyophilised powder (>99% purity)
- Variants: 10 mg
- 🇦🇺 3–5 business days
March 2025
Best local supplier I've found
Ordered three times now. HPLC verification results have been consistent each time. The pathway browsing structure makes it much easier to compare compounds.
Sarah K.
Melbourne, AU
Fast shipping, great documentation
Same-day dispatch on my last two orders. The batch COA was easy to locate and the product information pages are genuinely useful for research planning.
Michael T.
Brisbane, AU
Representative of verified researcher feedback.
Overview
What Is CJC-1295 No DAC?
CJC-1295 without DAC (Modified GRF 1-29) is a growth hormone-releasing hormone analogue used in research protocols studying pulsatile GH secretion. Its shorter half-life compared to the DAC variant makes it suitable for protocols requiring discrete GH pulse stimulation.
Also known as Modified GRF 1-29, CJC-1295 No DAC is supplied as a lyophilised research peptide for laboratory use only. Research demonstrates CJC-1295 (no DAC) stimulates GH release via GHRH receptor activation with a half-life of approximately 30 minutes, producing discrete GH pulses rather than sustained elevation. It is commonly studied in combination with selective GHRPs for synergistic GH output.
Mechanism
How CJC-1295 No DAC Works — Research Mechanism
Research demonstrates CJC-1295 (no DAC) stimulates GH release via GHRH receptor activation with a half-life of approximately 30 minutes, producing discrete GH pulses rather than sustained elevation. It is commonly studied in combination with selective GHRPs for synergistic GH output.
- Primary research focus: growth-hormone, ghrh, performance
- Mechanism studied in published preclinical and clinical literature
- Third-party HPLC/MS identity verification on every EvoPeak batch
- Supplied strictly for laboratory research use
Research reference
CJC-1295 No DAC Dosage — Published Research Protocols
The following reference points are drawn from published research literature. These figures are provided for research reference only and do not constitute dosing recommendations. CJC-1295 No DAC is sold strictly for laboratory research use.
| Protocol tier | Published research detail |
|---|---|
| Research reference | Published literature varies by model and endpoint — consult primary sources for protocol-specific dosing in laboratory settings |
| Administration route | Subcutaneous injection is most common in published peptide research protocols |
| Frequency | Dosing frequency depends on compound half-life and research design — daily to weekly intervals reported in literature |
| Available vial sizes | 10 mg — select based on your laboratory protocol requirements |
| Titration | Many research protocols start at lower doses and escalate to assess receptor response and tolerability in models |
Research use only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Safety research
CJC-1295 No DAC Side Effects — Research Findings
Side effect profiles documented in published CJC-1295 No DAC research depend on dose, route of administration, and model system. The following are commonly reported findings from research literature — not from personal use contexts.
- Injection site reactions common to peptide administration routes
- Transient water retention reported in some GH-axis research models
- Headache and mild fatigue documented in GHRH/GHRP combination studies
- Effects generally resolve with dose adjustment in published protocols
Handling
Reconstituting CJC-1295 No DAC
CJC-1295 No DAC is supplied as a lyophilised powder and must be reconstituted before use in laboratory protocols. Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Inject diluent slowly down the inside wall of the vial — do not shake vigorously.
Bacteriostatic water is available from EvoPeak. Store reconstituted peptide at 2–8°C and lyophilised powder at −20°C.
Shop bacteriostatic waterAustralia
How to Get CJC-1295 No DAC in Australia
Researchers in Australia can source CJC-1295 No DAC through EvoPeak — a local supplier offering third-party tested research compounds with batch-specific COA documentation and domestic shipping.
- 1
Browse CJC-1295 No DAC variants (10 mg) on the EvoPeak product page
- 2
Review the certificate of analysis (COA) for HPLC purity and mass spectrometry identity verification
- 3
Select your vial size and add to cart — prices include GST with same-day Australian dispatch
- 4
Receive your order with batch-specific quality documentation for laboratory traceability
Quality Standard
Research compounds need evidence, not guesswork.
Every shopping path leads back to the same core standard: research-use positioning, third-party quality signals, transparent documentation, and careful handling guidance.
HPLC/MS verified
Purity and identity checks support confident compound selection for controlled research.
Endotoxin screened
Quality review extends beyond purity so researchers can evaluate handling risk.
Batch documentation
COA-first product pages keep quality signals close to every purchase decision.
Australia shipped
Local fulfilment keeps delivery predictable for Australian research customers.
FAQ
CJC-1295 No DAC — Common Questions
What is CJC-1295 No DAC?
Short-acting GHRH analogue for pulsatile growth hormone research. CJC-1295 without DAC (Modified GRF 1-29) is a growth hormone-releasing hormone analogue used in research protocols studying pulsatile GH secretion. Its shorter half-life compared to the DAC variant ma… It is supplied for laboratory research use only.
What is the CJC-1295 No DAC dosage used in research?
Published research uses varying doses depending on the model and endpoint. EvoPeak supplies 10 mg vials. All dosage information is for research reference only and does not constitute recommendations.
What are the side effects of CJC-1295 No DAC?
Side effect profiles in published research depend on dose, route, and model system. Consult primary literature for compound-specific findings. All information is drawn from research contexts, not personal use.
Can I buy CJC-1295 No DAC in Australia?
Yes. EvoPeak supplies research-grade CJC-1295 No DAC to Australian researchers with HPLC/MS verification, batch-specific COA documentation, and domestic shipping. Products are for laboratory research use only.
How do I get CJC-1295 No DAC in Australia?
Order from the EvoPeak shop page, select your vial size, review the COA, and checkout with local Australian fulfilment.
How do I reconstitute CJC-1295 No DAC?
CJC-1295 No DAC is supplied as lyophilised powder. Reconstitute with bacteriostatic water, inject diluent slowly down the vial wall without shaking, and store at 2–8°C once reconstituted. Bacteriostatic water is available from EvoPeak.
What purity standard does EvoPeak CJC-1295 No DAC meet?
Every batch undergoes HPLC purity analysis (targeting >99%), mass spectrometry identity verification, and endotoxin screening. Batch-specific COAs are available on the product page.
Is cjc-1295 no dac peptide the same as Modified GRF 1-29?
CJC-1295 No DAC is also known as Modified GRF 1-29. Both refer to the same research compound supplied by EvoPeak.
Ready to order CJC-1295 No DAC?
Third-party HPLC/MS tested with batch-specific COA documentation. Shipped from Australia for laboratory research use only.